Latest Articles
FAPI PET/MRI detects more endometriosis lesions than MRI alone - AuntMinnieEurope
FAPI PET/MRI detects more endometriosis lesions than MRI alone AuntMinnieEurope
Published: June 22, 2026, 9:16 p.m.
Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer - OncLive
Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer OncLive
Published: June 20, 2026, 1:04 p.m.
Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer - OncLive
Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer OncLive
Published: June 19, 2026, 5:49 p.m.
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer Targeted Oncology
Published: June 19, 2026, 5:05 p.m.
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? - ESMO Daily Reporter
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? ESMO Daily Reporter
Published: June 18, 2026, 2:24 p.m.
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference
Published: June 17, 2026, 2:51 p.m.
Hospital charity launches £1.5m MRI appeal to support 1,300 women and babies every year - Greater Birmingham Chambers of Commerce
Hospital charity launches £1.5m MRI appeal to support 1,300 women and babies every year Greater Birmingham Chambers of Commerce
Published: June 12, 2026, 5:07 a.m.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies - The Malaysian Reserve
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies The Malaysian Reserve
Published: June 11, 2026, 6:33 a.m.
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies - StreetInsider
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies StreetInsider
Published: June 11, 2026, 5:42 a.m.
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer - The ASCO Post
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer The ASCO Post
Published: June 10, 2026, 4:41 p.m.
Link copied to clipboard!